Novartis gets EC approval for self-administration of Xolair across all indications

Novartis gets EC approval for self-administration of Xolair across all indications

Source: 
Pharmaceutical Business Review
snippet: 

Novartis has secured approval from the European Commission (EC) for Xolair (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.